OncoMatch/Clinical Trials/NCT06986174
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Is NCT06986174 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pacritinib for waldenström macroglobulinemia.
Treatment: Pacritinib — This study is being done to examine the safety and effectiveness of pacritinib as a possible treatment for participants with Waldenström macroglobulinemia (WM). The name of the study drug involved in this study is: -Pacritinib (a type of kinase inhibitor)
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
absolute neutrophil count ≥0.5 k/uL without growth factor within 7 days; platelet count ≥50 k/uL without platelet transfusion within 7 days
Kidney function
Creatinine clearance ≥30 ml/min using Cockcroft/Gault equation
Liver function
total bilirubin ≤1.5x ULN or ≤3x ULN with documented liver involvement, hemolysis or Gilbert's disease; AST (SGOT) and ALT (SGPT) ≤2.5x ULN or ≤5x ULN with documented liver involvement
Cardiac function
Significant cardiovascular disease defined as: unstable angina, history of myocardial infarction within 6 months, LVEF ≤45% in prior 12 months, NYHA Class 3 or 4 cardiac disease, uncontrolled or symptomatic arrhythmias; Prolonged QT Interval with baseline QTc >480 msec using Bazette formula
Participants must meet the following organ and marrow functions as defined below: absolute neutrophil count ≥0.5 k/uL without growth factor within 7 days; platelet count ≥50 k/uL without platelet transfusion within 7 days; total bilirubin ≤1.5x ULN or ≤3x ULN with documented liver involvement, hemolysis or Gilbert's disease; AST (SGOT) and ALT (SGPT) ≤2.5x ULN or ≤5x ULN with documented liver involvement; Creatinine clearance ≥30 ml/min using Cockcroft/Gault equation; Significant cardiovascular disease defined as: unstable angina, history of myocardial infarction within 6 months, LVEF ≤45% in prior 12 months, NYHA Class 3 or 4 cardiac disease, uncontrolled or symptomatic arrhythmias; Prolonged QT Interval with baseline QTc >480 msec using Bazette formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify